NVL-655, also known as Zidesamtinib, is a next-generation, selective ALK inhibitor developed by Nuvalent, under clinical investigation for ALK-positive cancers, including resistant mutations.
CAS: { 2739829-00-4 }
Purity: ≥{98.6%}% (HPLC)
Stock: {586kg}
MOQ: {MOQ}（sample: 1 g）
Lead time: Samples: 3–5 days; Batch: 7–21 days
Documents: COA / HPLC / NMR / MSDS (available on request)
Physicochemical Properties
| M.Wt | 419.46 | |
| Formula | C22H22FN7O | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility | 10 mM in DMSO | |
| Chemical Name/SMILES | (14R)-7-Ethyl-16-fluoro-2,14-dihydro-2,14-dimethyl-7H-8,12-metheno-4H-pyrazolo[3,4-h]-1,2,3-triazolo[4,5-k][2,5]benzoxaazacyclotetradecin-11-amine | |
As a dedicated supplier of pharmaceutical intermediates and APIs, EOS Med CDMO offers Zidesamtinib for research and development use, We support scale-up production up to kilogram levels and provide full Drug Master File (DMF) documentation support. Every shipment comes with complete technical dossiers, including COA, MSDS, and analytical data (HPLC/HNMR), to ensure seamless regulatory compliance for your project.
Specifications
CAS:2739829-00-4
Synonyms: NVL655, Zidesamtinib
Target: ALK (next-gen selective)
Research Area: ALK-positive cancers
Transportation Conditions: This product is a non-hazardous chemical and should be transported at room temperature. It can be stably stored for several weeks during normal transportation and customs clearance.
Storage Conditions: Short-term (days to weeks) storage at 0-4°C; long-term (months to years) storage at -20°C.
Solubility: To be determined.
Shelf Life: Over 2 years under proper storage conditions.
Pharmaceutical Preparations: To be determined.
HS Code: 2934.99.9001